Fresenius Kabi Biosimilars
The Biosimilars business was acquired by Fresenius Kabi in 2017 and the Fresenius Kabi SwissBioSim GmbH was founded in the same year with its Global Headquarter in Eysins, Switzerland.
With our expertise in biosimilars, we develop products with a focus on autoimmune diseases and oncology. Building on our company legacy our purpose is to provide high-quality, competitive and affordable medicines to more healthcare providers and patients around the world.
In 2019, we launched our first biosimilar in Europe and inaugurated a new state-of-the art Research & Development Laboratory to support our ongoing product development and enhancement of our pipeline.